Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study

被引:14
|
作者
Valenzuela-Vallejo, Laura [1 ]
Chrysafi, Pavlina [1 ]
Kouvari, Matina [1 ]
Guatibonza-Garcia, Valentina [1 ]
Mylonakis, Sophia C. [1 ]
Katsarou, Angeliki [1 ]
Verrastro, Ornella [2 ]
Markakis, Georgios [3 ]
Eslam, Mohammed [4 ,5 ]
Papatheodoridis, Georgios [3 ]
Mingrone, Geltrude [2 ]
George, Jacob [4 ,5 ,7 ]
Mantzoros, Christos S. [6 ]
机构
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
[2] Univ Cattolica Sacro Cuore, Dept Gastroenterol, Rome, Italy
[3] Natl & Kapodistrian Univ Athens, Gen Hosp Athens Laiko, Med Sch, Dept Gastroenterol, Athens, Greece
[4] Westmead Hosp, Storr Liver Ctr, Westmead Inst Med Res, Sydney, NSW, Australia
[5] Univ Sydney, Sydney, NSW, Australia
[6] Boston VA Healthcare Syst, Dept Med, Boston, MA 02130 USA
[7] Westmead Hosp, Westmead Inst Med Res, Sydney Med Sch, Sydney West Local Hlth Dist, 176 Hawkesbury Rd, Westmead, NSW 2145, Australia
来源
关键词
Metabolic dysfunction associated fatty liver disease (MASLD); Metabolic dysfunction associated steatohepatitis (MASH); Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic steatohepatitis (NASH); Metabolic-associated fatty liver disease (MAFLD); Fatty liver disease (FLD); Obesity; Diabetes; ACTIVIN-A; HEPATIC STEATOSIS; SCORING SYSTEM; ADIPONECTIN; LEPTIN; ASSOCIATION; FOLLISTATIN; VALIDATION; RISK; GH;
D O I
10.1016/j.metabol.2023.155694
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The role of metabolic/inflammatory hormonal systems in metabolic dysfunction associated steatotic liver disease (MASLD) remains to be fully elucidated.Purpose: To report the levels of the novel total and H-specific growth differentiation factor-15 (GDF-15) and other established hormonal systems and to describe hormonal patterns in controls and patients with MASLD and its stages.Methods: This is a multicenter study from two Gastroenterology-Hepatology Departments (Greece and Australia) and one Bariatric-Metabolic Surgery Department (Italy). Overall, n = 455 serum samples of patients with biopsy -proven MASLD (n = 374) and Controls (n = 81) were recruited.Results: We report for the first time that total and H-specific GDF-15 levels are higher in MASLD, at-risk metabolic dysfunction associated steatohepatitis (MASH), and severe fibrosis than in Controls. In addition, follistatin-like-3 (FSTL-3), free insulin-like growth factor-1 (IGF-1), leptin, and insulin levels were higher in MASLD patients than in Controls, while adiponectin levels were lower in MASLD subjects than in Controls. Activin-A, follistatin (FST), FSTL-3, and insulin levels significantly increased in severe fibrosis compared to no/mild fibrosis, while free IGF-1 decreased. In addition, adiponectin levels were lower in subjects without fibrosis vs. any fibrosis. Moreover, GDF-15 presented a strong positive association for the likelihood of having MASLD and at-risk MASH, while in adjusted analyses, FST and adiponectin showed inverse associations. Two different patterns of at-risk MASH were revealed through unsupervised analysis (total variation explained=54%). The most frequent pattern met in our sample (34.3%) was characterized by higher levels of total and H-specific GDF-15, follistatins, and activins, as well as low adiponectin levels. The second pattern revealed was characterized by high levels of free IGF-1, in-sulin, and leptin, with low levels of activin-A and adiponectin. Similar patterns were also generated in the case of overall MASLD.Conclusions: Total and H-specific GDF-15 levels increase as MASLD severity progresses. FSTL-3, free IGF-1, leptin, and insulin are also higher, whereas adiponectin and activin-A levels are lower in the MASLD group than in Controls. Hormonal systems, including GDF-15, may not only be involved in the pathophysiology but could also prove useful for the diagnostic workup of MASLD and its stages and may potentially be of therapeutic value.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Serum Metabolites Are Associated With HFpEF in Biopsy-Proven Nonalcoholic Fatty Liver Disease
    Wegermann, Kara
    Fudim, Marat
    Henao, Ricardo
    Howe, Catherine F.
    McGarrah, Robert
    Guy, Cynthia
    Abdelmalek, Manal F.
    Diehl, Anna Mae
    Moylan, Cynthia A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (14):
  • [32] EARLY CARDIAC DYSFUNCTION IN BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Johnson, Peter C.
    Cochet, Anthony A.
    Gore, Rosco S.
    Harrison, Stephen A.
    Magulick, John P.
    Aden, James K.
    Paredes, Angelo H.
    GASTROENTEROLOGY, 2018, 154 (06) : S1174 - S1174
  • [33] Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease
    Senates, Ebubekir
    Yilmaz, Yusuf
    Colak, Yasar
    Ozturk, Oguzhan
    Altunoz, Mustafa Erhan
    Kurt, Ramazan
    Ozkara, Selvinaz
    Aksaray, Sebahat
    Tuncer, Ilyas
    Ovunc, Ayse Oya Kurdas
    METABOLIC SYNDROME AND RELATED DISORDERS, 2011, 9 (04) : 287 - 290
  • [34] Biopsy-proven Non-alcoholic Fatty Liver Disease and Incident Cancer
    Kim, Hee Yeon
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2021, 78 (06): : 362 - 363
  • [35] Circulating PCSK9 levels correlated with advanced disease in patients with biopsy-proven non-alcoholic fatty liver disease
    Gato Zambrano, Sheila
    Munoz Hernandez, Rocio
    Montero-Vallejo, Rocio
    Rojas, Angela
    Maya, Douglas
    Carmen Rico, M.
    Ampuero, Javier
    Romero Gomez, Manuel
    JOURNAL OF HEPATOLOGY, 2020, 73 : S434 - S435
  • [36] Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
    Arai, Taeang
    Atsukawa, Masanori
    Tsubota, Akihito
    Kato, Keizo
    Abe, Hiroshi
    Ono, Hirotaka
    Kawano, Tadamichi
    Yoshida, Yuji
    Tanabe, Tomohide
    Okubo, Tomomi
    Hayama, Korenobu
    Nakagawa-Iwashita, Ai
    Itokawa, Norio
    Kondo, Chisa
    Kaneko, Keiko
    Emoto, Naoya
    Nagao, Mototsugu
    Inagaki, Kyoko
    Fukuda, Izumi
    Sugihara, Hitoshi
    Iwakiri, Katsuhiko
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [37] Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study
    Huang, Daniel Q.
    Wilson, Laura A.
    Behling, Cynthia
    Kleiner, David E.
    Kowdley, Kris, V
    Dasarathy, Srinivasan
    Amangurbanova, Maral
    Terrault, Norah A.
    Diehl, Anna Mae
    Chalasani, Naga
    Neuschwander-Tetri, Brent A.
    Sanyal, Arun J.
    Tonascia, James
    Loomba, Rohit
    GASTROENTEROLOGY, 2023, 165 (02) : 463 - 472.e5
  • [38] Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
    Taeang Arai
    Masanori Atsukawa
    Akihito Tsubota
    Keizo Kato
    Hiroshi Abe
    Hirotaka Ono
    Tadamichi Kawano
    Yuji Yoshida
    Tomohide Tanabe
    Tomomi Okubo
    Korenobu Hayama
    Ai Nakagawa-Iwashita
    Norio Itokawa
    Chisa Kondo
    Keiko Kaneko
    Naoya Emoto
    Mototsugu Nagao
    Kyoko Inagaki
    Izumi Fukuda
    Hitoshi Sugihara
    Katsuhiko Iwakiri
    Scientific Reports, 11
  • [39] Gray Scale and Power Doppler Study of Biopsy-Proven Kikuchi Disease
    Yoo, Jung Lim
    Suh, Sang-il
    Lee, Young Hen
    Seo, Hyung Suk
    Kim, Kyoung Min
    Shin, Bong Kyung
    Song, Joon Young
    Seol, Hae Young
    JOURNAL OF ULTRASOUND IN MEDICINE, 2011, 30 (07) : 957 - 963
  • [40] Advanced Liver Fibrosis Predicts Liver Outcomes in Biopsy-proven Metabolic Dysfunction-associated Steatotic Liver Disease: A US-based Single-center Retrospective Cohort Study
    Lam, Robert
    Jain, Dhanpat
    Deng, Yanhong
    Acharya, Eesha
    Lim, Joseph K.
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2024, 12 (12) : 988 - 996